Zotatifin

DB16408InvestigationalSmall molecule

Zotatifin is under investigation in clinical trial NCT04092673 (Study of Eft226 in Subjects With Selected Advanced Solid Tumor Malignancies).

Mechanism: Pharmacologically active on Eukaryotic initiation factor 4A-I
Curator reviewed
Formula / weight: C₂₈H₂₉N₃O₅ · 487.556 g/mol (avg)
Code names: EFT-226 · WHO 10998

Resolves to

Compound

Structure

InChIKeyQYCXWOACFWMQFO-WZWZCULESA-NSMILESCOC1=NC(OC)=C2C(O[C@]3([C@@H]([C@@H](CN(C)C)[C@@H](O)[C@@]23O)C2=CC=CC=C2)C2=CC=C(C=C2)C#N)=C1

Targets

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

12+ReferencesStructured and connected to the statements they support

Which drugs share a target with Zotatifin, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.